A 2026 analysis of more than 25,000 septic adults in two US critical care databases scored sepsis-induced coagulopathy every day for a week. A score that stayed high marked patients at far higher risk of death. Much of that risk was severity already visible on day one, and the association held after adjustment for it. Early prophylactic heparin was associated with lower mortality, reaching significance in one database but not the other, and the randomized evidence stays neutral. We cover the design, the numbers as reported, what an observational landmark analysis cannot show, and what it means for nurses, pharmacists, advanced practice providers and intensivists. In this episode * In 20,168 MIMIC-IV patients and 5,829 eICU patients, a daily sepsis-induced coagulopathy score over the first 7 ICU days fell into three courses: persistently high, rising then falling, and resolving. * The persistently high course carried a subdistribution hazard ratio for in-hospital death by day 28 of 1.65 in MIMIC-IV, 95% confidence interval 1.52 to 1.78, and 1.73 in eICU, 1.51 to 1.99, but that group was sicker on day one, with a mean SOFA of 8.81 against 5.50 in the resolving group. * Prophylactic unfractionated heparin in the first 48 hours was associated with lower mortality in MIMIC-IV, 15.72% against 17.06%, subdistribution hazard ratio 0.908; the eICU estimate of 0.877 did not reach significance, and a 2024 meta-analysis of 3 trials with 426 patients found a neutral risk ratio of 0.86. * Everything needed to score SIC is drawn every morning: platelets, INR and the SOFA organ component, with a total of 4 or more positive. ICCN recommends scoring it daily and treating a score that will not come down as a prompt for a differential, not a treatment target. * Keep prophylactic heparin decisions on VTE and bleeding grounds, and do not start therapeutic anticoagulation for sepsis-induced coagulopathy outside a clinical trial. Read the full article: https://iccn.substack.com/p/the-clotting-score-already-in-your?utm_source=podcast&utm_medium=audio&utm_campaign=q4_paid Sources * Cao Y, Wang M, Li Y, et al. Longitudinal sepsis-induced coagulopathy score trajectories and mortality in relation to early prophylactic heparin: a multicentre cohort study. Front Cell Infect Microbiol. 2026;16:1923833. doi:10.3389/fcimb.2026.1923833 * Iba T, Helms J, Levy JH. Sepsis-induced coagulopathy (SIC) in the management of sepsis. Ann Intensive Care. 2024;14:148. doi:10.1186/s13613-024-01380-5 * Totoki T, Koami H, Makino Y, et al. Heparin therapy in sepsis and sepsis-associated disseminated intravascular coagulation: a systematic review and meta-analysis. Thromb J. 2024;22:84. doi:10.1186/s12959-024-00653-0 * Radermacher PB, Fujita B, Vahldieck C. Early systemic heparin exposure is associated with lower mortality, reduced disseminated intravascular coagulation, and fewer thrombotic complications in septic shock. Front Med (Lausanne). 2026;13:1931895. doi:10.3389/fmed.2026.1931895 * Matsuoka T, Yamakawa K, Umemura Y, et al. The transition of the criteria for disseminated intravascular coagulation and the targeted patients in randomized controlled trials over the decades: a scoping review. Thromb J. 2024;22:112. doi:10.1186/s12959-024-00681-w ICCN publishes one article a day for ICU clinicians. $8 a month or $80 a year, with a 7-day free trial. This episode is for educational purposes for healthcare professionals. It is not medical advice, a clinical guideline or a standard of care. Clinical decisions must be individualized by qualified clinicians. Hosted by Javier Amador-Castaneda, BHS, RRT, FCCM. Voices rendered with AI text-to-speech from a script written and reviewed by ICCN. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit iccn.substack.com/subscribe
